

Supplementary table. List of clinical practice guidelines for the management of ovarian cancer			
Country	Organization	Included guideline(s)	Years published/ revised
Norway	Norwegian Directorate of Health (NDH)	Gynecological cancer - national action programme with guidelines for diagnosis, treatment and follow-up ¹	2016
Australia	Cancer Australia (CA)	Recommendations for the management of women at high risk of ovarian cancer ² Recommendations for the use of first-line chemotherapy for the treatment of women with epithelial ovarian cancer ³ Optimal Care Pathway for Women with Ovarian Cancer ⁴	2004, 2011 2004, 2014, 2016
Denmark	Danish Gynaecological Cancer Group (DGCG)	National Ovarian Cancer Guidelines ⁵	2003, 2007, 2010, 2014 2017
Canada	Alberta Health Services	Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer ⁶	2011, 2012, 2013
	British Columbia Cancer	Ovary – Epithelial Carcinoma ⁷	2018
	Cancer Care Ontario (CCO)	The Role of Intraperitoneal Chemotherapy in the First-line Treatment of Women with Stage III Epithelial Ovarian Cancer ⁸	2006, 2012
		Management of a suspicious adnexal mass ⁹	2011, 2016
		First-line Chemotherapy for Postoperative Patients with Stage II, III or IV Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer ¹⁰ Organizational Guideline for Gynecologic Oncology Services in Ontario Systemic Therapy for Recurrent Epithelial Ovarian Cancer ¹¹ Serous Epithelial Ovarian Cancer Treatment and Follow-up Pathway Map ¹²	2001, 2004, 2012, 2013 2003, 2006, 2011, 2016, 2018
UK	National Institute for Health and Care Excellence (NICE)	Ovarian cancer: recognition and initial management ¹³	2011
		Ultra-radical (extensive) surgery for advanced ovarian cancer ¹⁴	2013
		Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer ¹⁵	2013
		Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy ¹⁶	2019
Scotland	British Gynaecological Cancer Society (BGCS) Scottish Intercollegiate Guidelines Network (SIGN)	Epithelial Ovarian / Fallopian Tube / Primary Peritoneal Cancer Guidelines: Recommendations for Practice ¹⁷	2017
		Management of epithelial ovarian cancer ¹⁸	2003, 2013, 2018
South Wales	South Wales Cancer Network (SWCN)	South Wales Gynaecology Clinical Guidelines ¹⁹	2011
North Wales	North Wales Cancer Network (NWCN)	North Wales Ovarian Cancer Guidelines ²⁰	2015
Northern Ireland	Northern Ireland Cancer Network (NICaN)	Systematic Anti-Cancer Therapy (SACT) Guidelines for Ovarian Cancer ²¹	2017
New Zealand	New Zealand Ministry of Health (NZMH)	Standards of Service Provision for Gynaecological Cancer Patients in New Zealand – <i>Provisional</i> ²²	2013
Ireland	National Cancer Control Programme (NCCP)	-	-
Other international guidelines	National Comprehensive Cancer Network (NCCN) American Society of Clinical Oncology (ASCO) European Society of Medical Oncology (ESMO) European Society of Gynaecological Oncology (ESGO)	Epithelial Ovarian Cancer ²³	2019*
		Neoadjuvant Chemotherapy for Ovarian Cancer ²⁴	2016
		Newly Diagnosed and Relapsed Epithelial Ovarian Carcinoma: ESMO Clinical Practice Guidelines ²⁵	2013, 2016
		Ovarian Cancer Surgery Guidelines ²⁶	2017

*Updated on a continuous basis, at least annually

Additional references:

- ¹Norwegian Directorate for Health (NDH). Gynecological cancer - national action programme with guidelines for diagnosis, treatment and follow-up. NDH National Professional Guidelines 2016. Available at: <https://www.helsedirektoratet.no/retningslinjer/gynekologisk-kreft-handlingsprogram>
- ²National Breast and Ovarian Cancer Centre (NBOCC). Recommendations for the management of women at high risk of ovarian cancer. Cancer Australia 2011. Available at: https://guidelines.canceraustralia.gov.au/guidelines/guideline_14.pdf
- ³Cancer Australia. Recommendations for the use of first-line chemotherapy for the treatment of women with epithelial ovarian cancer. Australian Government 2014. Available at: <https://canceraustralia.gov.au/publications-and-resources/clinical-practice-guidelines/first-line-chemotherapy-treatment-women-epithelial-ovarian-cancer>
- ⁴Cancer Australia. Optimal Care Pathway for Women with Ovarian Cancer. Australian Government 2016. Available at: <https://www.cancer.org.au/content/ocp/health/optimal-care-pathway-for-women-with-ovarian-cancer-june-2016.pdf>
- ⁵Danish Gynaecological Cancer Group (DGCG). National Ovarian Cancer Guidelines: Recommendations for the management of all histological subtypes. DGCG 2018.
- ⁶Alberta Health Services (AHS). Epithelial Ovarian, Fallopian Tube and Peritoneal Cancer. AHS 2013. Available at: <https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-gyne005-epithelialovarian.pdf>
- ⁷British Columbia (BC) Cancer. Ovary – Epithelial Carcinoma. BC Cancer 2018. Available at: <http://www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-management-guidelines/gynecology/ovary-epithelial-carcinoma>
- ⁸Members of the Gynecology Cancer Disease Site Group. The Role of Intraperitoneal Chemotherapy in the First-line Treatment of Women with Stage III Epithelial Ovarian Cancer. Cancer Care Ontario (CCO) 2012.
- ⁹Dodge J, Covens A, Lacchetti C, Elit L, Le T, Devries-Aboud M et al. Management of a suspicious adnexal mass. Cancer Care Ontario (CCO) 2016.
- ¹⁰Members of the Gynecology Cancer Disease Site Group. First-line Chemotherapy for Postoperative Patients with Stage II, III or IV Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. Cancer Care Ontario (CCO) 2013.
- ¹¹Fung-Kee-Fung M, Kennedy E, Biagi J, Colgan T, D'Souza D, Elit L, Hunter A, et al. Organisational guideline for Gynecologic Oncology services. Cancer Care Ontario (CCO) 2013. Available at:
- ¹²Cancer Care Ontario. Serous Epithelial Ovarian Cancer Treatment and Follow-up Pathway Map (version 2018.06). Available at: <https://www.cancercareontario.ca/sites/ccocancercare/files/assets/CCOOvarySerousTreatmentPathway.pdf>
- ¹³National Institute of Health and Care Excellence NICE). Ovarian cancer: recognition and initial management. Clinical guideline [CG122]. 2011. Available at: <https://www.nice.org.uk/guidance/cg122>

-
- ¹⁴ National Institute of Health and Care Excellence (NICE). Ultra-radical (extensive) surgery for advanced ovarian cancer. Interventional procedures guidance [IPG470] 2013. Available at: <https://www.nice.org.uk/guidance/IPG470>
- ¹⁵ National Institute of Health and Care Excellence (NICE). Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer. NICE 2013.
- ¹⁶ NICE. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy [TA598]. Published 28th August 2019. Available at: <https://www.nice.org.uk/guidance/ta598>
- ¹⁷ Fotopoulou C, Hall M, Cruickshank D, Gabra H, Ganesan R, Hughes C, et al. Epithelial Ovarian / Fallopian Tube / Primary Peritoneal Cancer Guidelines: Recommendations for Practice. BGCS 2017
- ¹⁸ Scottish Intercollegiate Guidelines Network (SIGN). SIGN 135: Management of epithelial ovarian cancer. Health Improvement Scotland (HIS) 2013 [updated in 2018]
- ¹⁹ South Wales Cancer Network (SWCN). South Wales Gynaecology Clinical Guidelines. NHS Wales 2011.
- ²⁰ North Wales Cancer Network (NWCN) North Wales Cancer Guidelines: Ovarian Cancer. NHS Wales 2015.
- ²¹ McKenna S and Miller J. Systematic Anti-Cancer Therapy (SACT) Guidelines for Ovarian Cancer. Northern Ireland Cancer Network (NICAN) 2017.
- ²² National Gynaecological Cancer Tumour Standards Working Group. Standards of Service Provision for Gynaecological Cancer Patients in New Zealand – Provisional. Wellington: Ministry of Health 2013.
- ²³ National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Ovarian Cancer: including fallopian tube cancer and primary peritoneal cancer, version 2.2018. NCCN 2018.
- ²⁴ Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RI, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of gynecologic oncology and American society of clinical oncology clinical practice guideline. *J Clin Oncol* 2016;34:3460-73.
- ²⁵ Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, on behalf of the ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* 2013;24(6):24–32.
- ²⁶ Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, et al. European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. *Int J Gynecol Cancer* 2017.